1. Coverage Considerations for Novel Agents in Diabetes  AJMCtv
  2. ADA: J&J's struggling Invokana slashes heart, kidney risks in latest trial win  FiercePharma
  3. View full coverage on Google News
Johnson & Johnson and its fellow SGLT2 drugmakers are all working to show benefits for patients with kidney disease. But in that population, J&J is touting data its rivals don’t have.  Johnson & Johnson and its fellow SGLT2 drugmakers are all working to show benefits for patients with kidney disease. But in that population, J&J is touting data its rivals don’t have.  

ADA: J&J's struggling Invokana slashes heart, kidney risks in latest trial win | FiercePharma